The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Selecting Cities for User Research

September 1, 2010 12:36 pm | by Beth Loring | Blogs | Comments

Being a Human Factors/Usability professional, I’m often asked how to select cities for user research.   With market research, studies are often large and encompass a number of geographic regions in order to get a statistically significant sample. The focus is on what features a product should have and what will motivate people to buy the product.

Ethnofuturism for a Medical Future Perfect

September 1, 2010 12:24 pm | by James Rudolph | Blogs | Comments

The future perfect   By the time you arrive, I will have gone to the hospital.   This sentence is an example of the verb tense the future perfect. The unnerving reality of the future perfect is that it describes two or more independent variable actions that may occur in the future - always with a level of uncertainty. Naturally, we respond to the future perfect with mixed emotions: anxiety, skepticism, fear, perhaps a little excitement. It’s no surprise, then, that we respond to the idea of ethnofuturism (or, if you prefer, Futures Thinking) in much the same way. Ethnofuturism, like the future perfect, is research for the future, and understanding the future is never a perfect science.

Product Development Technologies Outlines Strategy for Successfully Designing for Developing Countries

September 1, 2010 12:11 pm | by Bob Coon. | Blogs | Comments

 Global design firm offers three guidelines for those looking to break into new markets.


Sustainability Scorecard: Kaiser Permanente Raising the Bar

September 1, 2010 11:55 am | by Chris Loughnane | Blogs | Comments

We [Kaiser Permanente] evaluated the four major players and found that clinical performance and pricing were comparable, but there were big differences in terms of sustainability performance," explained Robert Gotto, the executive director in Kaiser Permanente's Procurement & Supply group. "One supplier had the foresight to develop a camera that doesn't need to be sterilized with chemicals. It uses steam instead, and can cut down chemicals in operating room by half." So the steam-sterilized endoscope provider ended up getting the five-year, $100 million contract.

Select Medical completes Regency acquisition

September 1, 2010 11:45 am | by The Associated Press | News | Comments

Hospital operator Select Medical Holdings Corp. said Wednesday it finished a previously announced acquisition of Regency Hospital Co.Terms of the deal were not disclosed.As of June 30, Select Medical operated 89 long-term acute care hospitals and six acute medical rehabilitation hospitals in 25...

LifePoint completes $145M Sumner Regional deal

September 1, 2010 11:45 am | by The Associated Press | News | Comments

Hospital operator LifePoint Hospitals Inc. said Wednesday it completed its previously announced purchase of Sumner Regional Health Systems for $145 million plus working capital.Sumner, which will be renamed HighPoint Health System, employs more than 1,300 people and serves 11 Tennessee...

Ask The Experts-Adhesives Bonding

September 1, 2010 11:44 am | by Kyle Rhodes | Blogs | Comments

Question: Our tube set application uses a nylon tube bonded to a clear urethane tube, with a bond gap overlap of 0.010 inch x 0.004 inch thick bond gap. We have been looking at a DYMAX medical grade light-curable adhesive to bond the tube sets and get good adhesion, but we found that during our manufacturing run, some of the adhesive gets pushed inside the opaque nylon tube, and does not cure. Will this material cure by itself over time?

InfraReDx heart device gets FDA marketing approval

September 1, 2010 11:39 am | by Mass High Tech: The Journal of New England Technology | News | Comments

InfraReDx Inc., a Burlington-based medical device firm, has been granted clearance from the U.S. Food and Drug Administration to market its LipiScan IVUS Coronary Imaging System.


ESHRE's first workshop in Croatia: 'The determinants of a successful pregnancy'

September 1, 2010 11:39 am | by EurekAlert | News | Comments

(European Society of Human Reproduction and Embryology) The European Society of Human Reproduction and Embryology Special Interest Groups Reproductive Surgery, Early Pregnancy and Reproductive Endocrinology invite you to this campus course where scientists and clinicians will...


ISM manufacturing index picks up to 56.3%

September 1, 2010 11:37 am | by Material Handling Industry of America | News | Comments

U.S. manufacturing picked up its growth pace for the first time in four months, the Institute for Supply Management (ISM) reported. The ISM index rose to 56.3% in August from 55.5% in July. This was much stronger than expected."Manufacturing activity

European Interspinous Process Decompression Device Market Will Grow Nominally at 1.2% over the Next Five Years

September 1, 2010 11:36 am | by Bio-Medicine.Org | News | Comments

TORONTO, Sept. 1 / - According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, although interspinous process decompression devices will continue to be used in a narrow set of indications over the next five years in Europe, the market...


Varian Medical Systems Establishes Radiotherapy Training Center in Mumbai, India

September 1, 2010 11:36 am | by Bio-Medicine.Org | News | Comments

MUMBAI, India, Sept. 1 /- Varian Medical Systems (NYSE: VAR ), a world leader in radiotherapy equipment and software, has established its first education center in India to train medical physicists and technologists working on the company's advanced cancer treatment systems. The center in...


U.S. Court of Appeals Upholds Validity of Lilly's Evista Patents Through March of 2014

September 1, 2010 11:36 am | by Bio-Medicine.Org | News | Comments

INDIANAPOLIS, Sept. 1 /- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the Southern District of Indiana that the company's method-of-use patents for Evista®...


The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer

September 1, 2010 11:36 am | by Bio-Medicine.Org | News | Comments

COLD SPRING HARBOR, N.Y., Sept. 1 /- The ASCO Post captured initial reactions to the Oncologic Drugs Advisory Committee (ODAC) recommendation that the breast cancer indication for bevacizumab (Avastin) be revoked in interviews with ODAC voting members, breast cancer specialists,...


QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR

September 1, 2010 11:36 am | by Bio-Medicine.Org | News | Comments

SYDNEY, Australia and BEDMINSTER, N.J., Sept. 1 /- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission. The analysis indicated the planned sample size of 140...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.